Systemic sclerosis & Raynaud's
Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life
Authors' conclusion
MMF use in SSc appears to be limited by the occurrence of AEs, both in terms of persistence and dosing of the drug.
Study context
- Population
- SSc patients who started MMF treatment, real-life setting
- Participants
- 554 patients
- Outcome
- MMF retention rate
- Follow-up
- Up to 5 years
Methodological detailslongitudinal, up to 5 years
- Longitudinal
- Up to 5 years
Main finding
As reported in the abstract
MMF
70.7%
Observational data: associations, not effects.
Further findings
Post-MMF cessation strategies
- Most common approaches were 'watch and wait' and switch to rituximab
Safety
| Outcome | Values |
|---|---|
| MMF discontinuation due to AEs | MMF 19.6% |
MMF discontinuation due to adverse events (AEs)
- One in four patients had dose reduction or discontinuation due to AEs, gastrointestinal intolerance the predominant cause
5-year cumulative incidence of AEs leading to MMF discontinuation · up to 5 years
- Gastrointestinal intolerance
- 6.4%
- Cancer
- 4.1%
- Severe infections
- 3.1%
- Laboratory toxicity
- 2.1%
- Lower respiratory tract most affected by infection; bacteria predominant
Predictors of AEs and discontinuation
- Intestinal and pulmonary circulation involvement tied to elevated AE rates and MMF discontinuation
Original publication
Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life. Rheumatology (Oxford). Published 30 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →